Wendy’s Shares Fall after Guidance Cut
Wendy’s (NASDAQ:WEN) shares fell in early trading Friday after the fast-food restaurant chain slashed its forecast for the full year.For 2025, Wendy’s now expects adjusted earnings of 82 cents to 89 cents per share, down from its prior guidance of 92 cents to 98 cents per share and below the 94 cents that analysts polled by FactSet were anticipating.The company also now expects its global systemwide sales to fall between 3% and 5% for the year, while its previous guidance had called for flat to a 2% decline.“In the U.S., we have work to do to improve the overall performance of the business,” said Wendy’s interim CEO Ken Cook in a statement.For the second quarter, Wendy’s earnings and revenue topped estimates, however, posting adjusted earnings of 29 cents per share on revenue of $560.9 million compared to the 25 cents per share and $558 million in revenue that analysts were looking for, per FactSet."In the U.S., we have work to do to improve the overall performance of the business.” Cook continued, “We will continue to strengthen relationships with franchisees, improve the effectiveness of our marketing programs, and elevate the customer experience across the system. I'm confident that increasing our focus in these areas positions the Company for stronger long-term performance."WEN shares opened Friday lower 0.5 cents to $9.96.
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


